PTC Therapeutics, Inc. PTCT Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Apr 19, 2024 (filed on Apr 22, 2024)

Insider Name:

Klein Matthew B.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,361

Price:

$24.89
Apr 17, 2024 (filed on Apr 19, 2024)

Insider Name:

Pauwels Eric

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-787

Price:

$25.14
Apr 17, 2024 (filed on Apr 19, 2024)

Insider Name:

Klein Matthew B.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,307

Price:

$25.14
Apr 02, 2024 (filed on Apr 04, 2024)

Insider Name:

Golden Lee Scott

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-526

Price:

$28.37
Feb 15, 2024 (filed on Feb 16, 2024)

Insider Name:

Almstead Neil Gregory

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

47,500

Price:

--
Feb 15, 2024 (filed on Feb 16, 2024)

Insider Name:

Almstead Neil Gregory

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

870

Price:

--
Feb 15, 2024 (filed on Feb 16, 2024)

Insider Name:

Almstead Neil Gregory

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

6,000

Price:

--
Feb 15, 2024 (filed on Feb 16, 2024)

Insider Name:

Almstead Neil Gregory

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

19,000

Price:

--
Feb 15, 2024 (filed on Feb 16, 2024)

Insider Name:

Utter Christine Marie

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

35,000

Price:

--
Feb 15, 2024 (filed on Feb 16, 2024)

Insider Name:

Utter Christine Marie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

2,900

Price:

--

Filings by filing date

Apr 19, 2024 (filed on Apr 22, 2024)

Insider Name:

Klein Matthew B.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,361

Price:

$24.89
Apr 17, 2024 (filed on Apr 19, 2024)

Insider Name:

Pauwels Eric

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-787

Price:

$25.14
Apr 17, 2024 (filed on Apr 19, 2024)

Insider Name:

Klein Matthew B.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,307

Price:

$25.14
Apr 02, 2024 (filed on Apr 04, 2024)

Insider Name:

Golden Lee Scott

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-526

Price:

$28.37
Feb 15, 2024 (filed on Feb 16, 2024)

Insider Name:

Almstead Neil Gregory

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

47,500

Price:

--
Feb 15, 2024 (filed on Feb 16, 2024)

Insider Name:

Almstead Neil Gregory

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

870

Price:

--
Feb 15, 2024 (filed on Feb 16, 2024)

Insider Name:

Almstead Neil Gregory

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

6,000

Price:

--
Feb 15, 2024 (filed on Feb 16, 2024)

Insider Name:

Almstead Neil Gregory

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

19,000

Price:

--
Feb 15, 2024 (filed on Feb 16, 2024)

Insider Name:

Utter Christine Marie

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

35,000

Price:

--
Feb 15, 2024 (filed on Feb 16, 2024)

Insider Name:

Utter Christine Marie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

2,900

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	500 Warren Corporate Center Drive WARREN NJ 07059
Tel:	N/A
Website:	https://www.ptcbio.com
IR:	See website

Key People

Matthew B. Klein President, Chief Executive Officer, Director	Pierre Gravier Chief Financial Officer	Neil Almstead Chief Technical Operations Officer
Mark Elliott Boulding Executive Vice President, Chief Legal Officer	Christine Marie Utter Senior Vice President, Chief Accounting Officer, Head - People Services	Eric Pauwels Chief Business Officer

Business Overview

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Financial Overview

For the three months ended 31 March 2024, PTC Therapeutics, Inc. revenues decreased 5% to $210.1M. Net loss decreased 34% to $91.6M. Revenues reflect Net product revenue decrease of 5% to $177.6M, Manufacturing revenue decrease of 32% to $1.4M, Collaboration revenue decrease from $6K to $0K. Lower net loss reflects Non-GAAP research and development decrease of 40% to $107.2M (expense), Selling.

Employees:	988 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$3,445M as of Mar 31, 2024
Annual revenue (TTM):	$927.56M as of Mar 31, 2024
EBITDA (TTM):	$132.42M as of Mar 31, 2024
Net annual income (TTM):	-$579.22M as of Mar 31, 2024
Free cash flow (TTM):	-$85.92M as of Mar 31, 2024
Net Debt Last Fiscal Year:	$1,256M as of Mar 31, 2024
Shares outstanding:	76,696,785 as of Apr 23, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization